Eli Lilly and Company (LLY): We Sold Some Lilly, Says Jim Cramer

We recently published 12 Stocks Jim Cramer Recently Discussed As He Commented On A “Sea Of Green”. Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer recently discussed.

Weight loss drug giant Eli Lilly and Company (NYSE:LLY)’s shares have struggled in 2025 as they have lost 2.3% year-to-date. Yet, despite the stock’s woes, Cramer has remained optimistic about the firm. While the CNBC host has reduced the frequency of discussions surrounding Eli Lilly and Company (NYSE:LLY) lately, his earlier remarks have not only praised the firm’s lead in the weight loss drug industry but also cited hope for a robust drug pipeline and plans to expand manufacturing presence in the US. This time, he commented that Eli Lilly and Company (NYSE:LLY) is better than Novo Nordisk:

“[On LLY shares being down] Right, I mean we sold some Lilly for the trust. I mean, Lilly’s just back to where it was last week. Lilly’s better.

“And their’s is the better product too. . .”

Here are Cramer’s previous comments about Eli Lilly and Company (NYSE:LLY):

“What I’m thinking, as someone who owns Eli Lilly for the Charitable Trust and who wishes I owned PepsiCo, is that there might be a short-term peak in the use of these drugs (GLP-1s). The Achilles heel of these drugs is that they’re too effective. At some point, you lose enough weight, and you might think you can stop taking them… Whatever the case, if Eli Lilly is going to break out from this level, it needs breakthroughs in new areas, heart, brain, that it just doesn’t have right now, or there has to be some new data that shows something else positive that the GLP-1 drugs can do.

And of course, it’s got to start coming in pill form because people are tired of taking needles. I still like the stock of Eli Lilly. We have a huge gain in this one for the Charitable Trust. We’re going to hang on to it for now. But PepsiCo’s breakout, a lack of Lilly’s breakthroughs, and a reminder that at one point we were thinking of buying the airlines because of these GLP-1 drugs means that I no longer feel as certain about Lilly’s future without science that says these drugs do a lot more than just control diabetes and make you lose some weight.”

While we acknowledge the potential of LLY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.